.Charles Baum, M.D., Ph.D., who supervised Mirati Rehabs' $ 5.8 billion sale to Bristol Myers Squibb in 2014, is actually taking the command of young biotech Terremoto Biosciences.Baum's "comprehensive adventure in medication development, as well as tested record ahead of time high-impact medicines, will definitely contribute," outbound chief executive officer Peter Thompson, M.D., mentioned in a July 25 release. Thompson will retain his seat as board chairperson..Baum, an experienced physician-scientist, was actually the owner, president and CEO of oncology-focused Mirati. Before that, he aided establish cancer cells medications at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum will certainly work as CEO at Terremoto, a company cultivating tiny particles to target disease-causing healthy proteins-- like those discovered in cancerous lump tissues-- making use of covalent connections. Existing treatments that utilize covalent connects primarily target the amino acid cysteine. Having said that, of the 20 amino acids that compose healthy proteins, cysteine is the least common. Terremoto is actually rather targeting one of the important amino acids, lysine, which is found in nearly all proteins.Through targeting amino acid lysine as well as various other amino acids, Terremoto hopes to treat formerly undruggable diseases and also produce first-in-class medications..The biotech, located in South San Francisco, raised $75 thousand in series A funding in 2022. A little bit of greater than a year later on, the biotech much more than multiplied that variety in a $175 million collection B.